Coronary Disease Clinical Trial
Official title:
The Official Title is in French: Microbiote, Acides Biliaires et Athérome Coronaire (MABAC)
The purpose of this study is to describe the composition of bile acids and the gut
microbiota comparing two populations: patients with coronary atheroma and the healthy
subjects.
Our hypothesis is based on the demonstration of the anti atherogenic and anti inflammatory
effect of certain bile acids, and the role of the gut microbiota in the metabolic
regulation.
Atherosclerosis is the main cause of cardiovascular diseases which remain the first cause of
death worldwide. The prevention of risk factors can reduce the development of cardiovascular
diseases. The final goal of our study is to find new protective or new risk factors that can
be modulated to reduce the incidence of cardiovascular events.
Gut microbiota and its main metabolite, the bile acids, are implicated in the metabolic
regulation. Some bile acids, especially the secondary bile acids, transformed from the
primary bile acids by the bacteria of the gut microbiota, are now demonstrated in murine
experimental atherosclerosis models, to be anti inflammatory and anti atherogenic molecules.
We want to compare the pool of bile acids and the composition of gut microbiota between the
coronary patients and the healthy subjects to identify the potential protective or
deleterious bacteria / bile acids.
All patients admitted for a scheduled coronary angiogram will be included, then divided into
two groups: coronary or healthy, based on the presence or the absence of atheroma during the
coronary angiogram.
Feces and blood samples, and clinical and biological data, will be collected during the
patient's hospitalisation. No additional exam will be performed. The blood sample will be
collected during the coronary angiogram or during a routine blood test.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Completed |
NCT05672862 -
International Post-PCI FFR Extended Registry
|
||
Completed |
NCT04492423 -
VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
|
||
Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Completed |
NCT00046410 -
Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting
|
N/A | |
Recruiting |
NCT04390672 -
Multivessel TALENT
|
N/A | |
Completed |
NCT02784873 -
High Intensity Interval Training in UK Cardiac Rehabilitation Programmes
|
N/A | |
Not yet recruiting |
NCT02895009 -
Hemostatic Compression Patterns After Transradial Coronary Intervention
|
N/A | |
Completed |
NCT02948517 -
Time Restricted Feeding for Weight Loss and Cardio-protection
|
N/A | |
Recruiting |
NCT02859480 -
Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI
|
Phase 4 | |
Withdrawn |
NCT02418143 -
A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
|
||
Completed |
NCT02382731 -
Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction
|
N/A | |
Completed |
NCT02510547 -
Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial
|
Phase 4 | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Completed |
NCT02248415 -
Administration of Warm Blood Cardioplegia With or Without Roller Pump
|
N/A | |
Recruiting |
NCT01207167 -
Mediators of Atherosclerosis in South Asians Living in America
|
||
Completed |
NCT02088138 -
Functional Electrical Stimulation in Cardiac Patients
|
N/A | |
Completed |
NCT02133807 -
Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis
|
Phase 3 | |
Completed |
NCT02173067 -
Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective
|
N/A |